11:42 AM EST - Neovasc Inc. : Announced that following a trial in Boston, Massachusetts a jury found in favour of CardiAQ, on CardiAQ's claims for relief for breach of contract, breach of the duty of honesty in contractual performance, and three of CardiAQ's six asserted trade secrets. The jury also issued advisory findings in favor of CardiAQ regarding its causes of action under Massachusetts Gen. Law. Ch. 93A and patent inventorship. The jury awarded $70 million U.S. on the trade secret claim for relief, and no damages on the contractual claims for relief. Neovasc Inc.
shares T.NVC are trading down $1.88 at $0.52.
